Is there a place for cardiovascular magnetic resonance conditional devices in systemic inflammatory diseases?

Expert Review of Cardiovascular Therapy

Volumn 14, Issue 6, 2016, Pages 677-682

  Mavrogeni, Sophie I ^a   Poulos, George ^a   Sfikakis, Petros P ^b   Kitas, George D ^c   Kolovou, Genovefa ^a   Theodorakis, George ^a  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

atrioventricular block; Cardiac magnetic resonance conditional devices; systemic inflammatory diseases; ventricular fibrillation; ventricular tachycardia

Indexed keywords

GADOLINIUM;

ARTICLE; ATRIAL FIBRILLATION; ATRIOVENTRICULAR BLOCK; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; COMORBIDITY; FOLLOW UP; HEART EJECTION FRACTION; HEART MUSCLE CONDUCTION SYSTEM; HEART RIGHT VENTRICLE DYSPLASIA; HEART VENTRICLE CONDUCTION; HEART VENTRICLE TACHYCARDIA; HUMAN; IMAGE ENHANCEMENT; INFLAMMATORY DISEASE; LONG QT SYNDROME; MAGNETIC FIELD; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSPECTIVE STUDY; RECURRENCE RISK; SARCOIDOSIS; SCLERODERMA; SINUS TACHYCARDIA; SUDDEN CARDIAC DEATH; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; CARDIAC MUSCLE; CARDIOVASCULAR DISEASES; CINE MAGNETIC RESONANCE IMAGING; COMPLICATION; DEATH, SUDDEN, CARDIAC; DEVICES; EARLY DIAGNOSIS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; SCLERODERMA, SYSTEMIC;

CARDIOVASCULAR DISEASES; DEATH, SUDDEN, CARDIAC; EARLY DIAGNOSIS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MAGNETIC RESONANCE IMAGING, CINE; MYOCARDIUM; REPRODUCIBILITY OF RESULTS; SARCOIDOSIS; SCLERODERMA, SYSTEMIC;

EID: 84961206547     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2016.1154458     Document Type: Article

References (63)

1. P.M.Seferović, A.D.Ristić, R.Maksimović, et al. Cardiac arrhythmias and conduction disturbances in autoimmune rheumatic diseases. Rheumatology (Oxford). 2006;45(Suppl 4):iv39–42. doi:10.1093/rheumatology/kel315.•• This is the most documented paper about cardiac arrhythmias in SIDs.
2. S.Kumar, C.Barbhaiya, K.Nagashima, et al. Ventricular tachycardia in cardiac sarcoidosis: characterization of ventricular substrate and outcomes of catheter ablation. Circ Arrhythm Electrophysiol. 2015;8(1):87–93. doi:10.1161/CIRCEP.114.002145.
3. K.Yodogawa, Y.Seino, T.Ohara, et al. Effect of corticosteroid therapy on ventricular arrhythmias in patients with cardiac sarcoidosis. Ann Noninvasive Electrocardiol. 2011;16(2):140–147. doi:10.1111/j.1542-474X.2011.00418.x.
4. J.Kron, W.Sauer, G.Mueller, et al. Outcomes of patients with definite and suspected isolated cardiac sarcoidosis treated with an implantable cardiac defibrillator. J Interv Card Electrophysiol. 2015;43(1):55–64. doi:10.1007/s10840-015-9978-3.•• This is the most documented paper about outcomes of sarcoidosis treated with an implantable cardiac defibrillator.
5. P.E.Lazzerini, P.L.Capecchi, M.Acampa, et al. Arrhythmic risk in rheumatoid arthritis: the driving role of systemic inflammation. Autoimmun Rev. 2014;13(9):936–944. doi:10.1016/j.autrev.2014.05.007.
6. C.S.Crowson, K.P.Liao, J.M.Davis3rd, et al. Rheumatoid arthritis and cardiovascular disease. Am Heart J. 2013;166(4):622–628.e1. doi:10.1016/j.ahj.2013.07.010.
7. R.A.Teixeira, E.F.Borba, E.Bonfá, et al. Arrhythmias in systemic lupus erythematosus. Rev Bras Reumatol. 2010;50(1):81–89.
8. C.-N.Huang, H.-H.Yu, S.-N.Chiu, et al. Acute myocarditis and ventricular fibrillation as initial presentation of pediatric systemic lupus erythematosus. Rheumatol Int. 2013;33(4):1093–1096. doi:10.1007/s00296-011-2240-0.
9. G.Jindal, S.Singh, D.Suri, et al. Recurrent ventricular tachycardia in a child with juvenile dermatomyositis: an unusual association. Int J Rheum Dis. 2012;15(2):e26–7. doi:10.1111/j.1756-185X.2012.01701.x.
10. P.Dilaveris, P.Pietri, D.Tsiachris, et al. Inducible ventricular tachycardia due to dermatomyositis-related cardiomyopathy in the era of implantable cardioverter-defibrillator therapy. Circulation. 2012;125(7):967–969. doi:10.1161/CIRCULATIONAHA.111.049882.
11. M.Adler, S.Banerjeee, R.Stratton Ventricular tachycardia as a presenting feature of dermatomyositis. Heart. 2002;88(5):443. doi:10.1136/heart.88.5.443.
12. S.Mavrogeni, M.Douskou, M.N.Manoussakis Contrast-enhanced CMR imaging reveals myocardial involvement in idiopathic inflammatory myopathy without cardiac manifestations. JACC Cardiovasc Imaging. 2011;4(12):1324–1325. doi:10.1016/j.jcmg.2011.05.009.
13. P.B.Nery, R.S.Beanlands, G.M.Nair, et al. Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults. J Cardiovasc Electrophysiol. 2014;25(8):875–881. doi:10.1111/jce.12401.
14. H.Tsuchiya, H.Tsuno, S.Kaneko, et al. Complete atrioventricular block and aseptic meningitis in a patient with adult-onset Still’s disease and concurrent hemophagocytic syndrome. Mod Rheumatol. 2015;25(2):332–333. doi:10.3109/14397595.2014.882220.
15. P.Brito-Zerón, P.M.Izmirly, M.Ramos-Casals, et al. The clinical spectrum of autoimmune congenital heart block. Nat Rev Rheumatol. 2015;11(5):301–312. doi:10.1038/nrrheum.2015.29.
16. L.Bergfeldt, O.Edhag, L.Vedin, et al. Ankylosing spondylitis: an important cause of severe disturbances of the cardiac conduction system. Prevalence among 223 pacemaker-treated men. Am J Med. 1982;73(2):187–191.
17. O.Alyan, O.Ozdemir, B.Geyik, et al. Polymyositis complicated with complete atrioventricular block: a case report and review of the literature. Angiology. 2003;54(6):729–731.
18. S.Mavrogeni, E.Petrou, G.Kolovou, et al. Prediction of ventricular arrhythmias using cardiovascular magnetic resonance. Eur Heart J Cardiovasc Imaging. 2013;14(6):518–525. doi:10.1093/ehjci/jes302.• This an important review about the role of CMR in the evaluation of sudden death.
19. T.G.Neilan, H.Farhad, T.Mayrhofer, et al. Late gadolinium enhancement among survivors of sudden cardiac arrest. JACC Cardiovasc Imaging. 2015;8(4):414–423. doi:10.1016/j.jcmg.2014.11.017.
20. M.Chimura, K.Kiuchi, K.Okajima, et al. Distribution of ventricular fibrosis associated with life threatening ventricular tachyarrhythmias in patients with nonischemic dilated cardiomyopathy. J Cardiovasc Electrophysiol. 2015 Jul 29. doi:10.1111/jce.12767.
21. Z.Chen, M.Sohal, T.Voigt, et al. Myocardial tissue characterization by cardiac magnetic resonance imaging using T1 mapping predicts ventricular arrhythmia in ischemic and non-ischemic cardiomyopathy patients with implantable cardioverter-defibrillators. Heart Rhythm. 2015;12(4):792–801. doi:10.1016/j.hrthm.2014.12.020.
22. S.Mavrogeni, P.P.Sfikakis, G.Karabela, et al. “All roads lead to Rome” ventricular tachycardia due to right ventricle involvement in autoimmune and non-autoimmune disease. Int J Cardiol. 2014;173(1):126–127. doi:10.1016/j.ijcard.2014.02.019.
23. P.Molaee, K.S.Teo, D.T.Wong, et al. Cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis: presenting as ventricular tachycardia. Tex Heart Inst J. 2011;38(5):602–603.
24. T.Crawford, G.Mueller, S.Sarsam, et al. Magnetic resonance imaging for identifying patients with cardiac sarcoidosis and preserved or mildly reduced left ventricular function at risk of ventricular arrhythmias. Circ Arrhythm Electrophysiol. 2014;7(6):1109–1115. doi:10.1161/CIRCEP.113.000156.
25. S.Greulich, C.C.Deluigi, S.Gloekler, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6(4):501–511. doi:10.1016/j.jcmg.2012.10.021.
26. J.Nadel, T.Lancefield, A.Voskoboinik, et al. Late gadolinium enhancement identified with cardiac magnetic resonance imaging in sarcoidosis patients is associated with long-term ventricular arrhythmia and sudden cardiac death. Eur Heart J Cardiovasc Imaging. 2015;16(6):634–641. doi:10.1093/ehjci/jeu294.
27. K.Dohi, S.Nakamori, T.Kurita, et al. Arrhythmogenic right ventricular cardiomyopathy in a 20-year-old woman with systemic sclerosis. Intern Med. 2014;53(9):973–977.
28. S.Mavrogeni, P.P.Sfikakis, E.Gialafos, et al. Cardiac tissue characterization and the diagnostic value of cardiovascular magnetic resonance in systemic connective tissue diseases. Arthritis Care Res (Hoboken). 2014;66(1):104–112. doi:10.1002/acr.22181.
29. N.Varma, R.Hinojar, D.D’Cruz, et al. Coronary vessel wall contrast enhancement imaging as a potential direct marker of coronary involvement: integration of findings from CAD and SLE patients. JACC Cardiovasc Imaging. 2014 Aug;7(8):762–770. doi:10.1016/j.jcmg.2014.03.012.
30. Y.Kobayashi, H.Kobayashi, J.T.Giles, et al. Association of tocilizumab treatment with changes in measures of regional left ventricular function in rheumatoid arthritis, as assessed by cardiac magnetic resonance imaging. Int J Rheum Dis. 2015 Oct 20. doi:10.1111/1756-185X.12632.
31. Y.Kobayashi, J.T.Giles, M.Hirano, et al. Assessment of myocardial abnormalities in rheumatoid arthritis using a comprehensive cardiac magnetic resonance approach: a pilot study. Arthritis Res Ther. 2010;12(5):R171. doi:10.1186/ar3131.
32. S.Mavrogeni, T.Dimitroulas, S.Gabriel, et al. Why currently used diagnostic techniques for heart failure in rheumatoid arthritis are not enough: the challenge of cardiovascular magnetic resonance imaging. Rev Cardiovasc Med. 2014;15(4):320–331.
33. T.Miszalski-Jamka, W.Szczeklik, B.Sokołowska, et al. Noncorticosteroid immunosuppression limits myocardial damage and contractile dysfunction in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). J Am Coll Cardiol. 2015;65(1):103–105. doi:10.1016/j.jacc.2014.08.055.
34. S.Mavrogeni, G.Karabela, E.Stavropoulos, et al. Heart failure imaging patterns in systemic lupus erythematosus. Evaluation using cardiovascular magnetic resonance. Int J Cardiol. 2014;176(2):559–561. doi:10.1016/j.ijcard.2014.07.016.
35. S.Mavrogeni, P.P.Sfikakis, G.Karabela, et al. Cardiovascular magnetic resonance imaging in asymptomatic patients with connective tissue disease and recent onset left bundle branch block. Int J Cardiol. 2014;171(1):82–87. doi:10.1016/j.ijcard.2013.11.059.
36. S.Mavrogeni, G.Karabela, E.Stavropoulos, et al. Imaging patterns of heart failure in rheumatoid arthritis evaluated by cardiovascular magnetic resonance. Int J Cardiol. 2013;168(4):4333–4335. doi:10.1016/j.ijcard.2013.05.085.
37. M.Barraclough, R.Elliott, S.McKie, et al. Cognitive dysfunction and functional magnetic resonance imaging in systemic lupus erythematosus. Lupus. 2015;24(12):1239–1247. doi:10.1177/0961203315593819.
38. E.Ercan, C.Ingo, O.Tritanon, et al. A multimodal MRI approach to identify and characterize microstructural brain changes in neuropsychiatric systemic lupus erythematosus. Neuroimage Clin. 2015;8:337–344. doi:10.1016/j.nicl.2015.05.002.
39. W.P.Nieuwenhuis, H.W.Van Steenbergen, W.Stomp, et al. The course of bone marrow edema in early undifferentiated and rheumatoid arthritis: a longitudinal MRI study on bone level. Arthritis Rheumatol. 2015 Dec 17. doi:10.1002/art.39550.
40. A.Berzigotti, M.Frigato, E.Manfredini, et al. Liver hemangioma and vascular liver diseases in patients with systemic lupus erythematosus. World J Gastroenterol. 2011;17(40):4503–4508. doi:10.3748/wjg.v17.i40.4503.
41. F.E.Lecouvet, N.Michoux, A.Nzeusseu Toukap, et al. The increasing spectrum of indications of whole-body MRI beyond oncology: imaging answers to clinical needs. Semin Musculoskelet Radiol. 2015 Sep;19(4):348–362. doi:10.1055/s-0035-1564695.
42. A.Y.Zhou, L.Muir, J.Harris, et al. The impact of magnetic resonance imaging in early diagnosis of hand osteomyelitis in patients with systemic sclerosis. Clin Exp Rheumatol. 2014;32(6 Suppl 86):S–232.
43. R.Kalin, M.S.Stanton. Current clinical issues for MRI scanning of pacemaker and defibrillator patients. Pace. 2005;28:326–328. doi:10.1111/j.1540-8159.2005.50024.x.
44. M.D.Lowe, C.J.Plummer, C.H.Manisty, et al. Safe use of MRI in people with cardiac implantable electronic devices. Heart. 2015;101(24):1950–1953. doi:10.1136/heartjnl-2015-308495.
45. F.Femenía, M.Arce, M.Arrieta. Systemic sclerosis complicated with syncope and complete AV block. Medicina (B Aires). 2010;70(5):442–444.
46. K.Oe, K.Mori, S.Gommori, et al. Syncope due to paroxysmal atrioventricular block in a patient with systemic sclerosis: a case report. Angiology. 2008;59(6):769–771. doi:10.1177/0003319707307216.
47. I.Moyssakis, D.P.Papadopoulos, A.G.Tzioufas, et al. Complete heart block in a patient with systemic sclerosis. Clin Rheumatol. 2006;25(4):551–552. doi:10.1007/s10067-005-0068-2.
48. K.Levesque, N.Morel, A.Maltret, et al., “Lupus néonatal” group; Group of collaborators. Description of 214 cases of autoimmune congenital heart block: results of the French neonatal lupus syndrome. Autoimmun Rev. 2015;14(12):1154–1160. doi:10.1016/j.autrev.2015.08.005.
49. S.Haydin, E.Ozturk, Y.Ergul, et al. Intrathoracic implantation of a dual-chamber pacemaker in a preterm infant with congenital AV block. J Card Surg. 2013;28(2):196–198. doi:10.1111/jocs.12068.
50. E.T.Martin, J.A.Coman, F.G.Shellock, et al. Magnetic resonance imaging and cardiac pacemaker safety at 1.5-tesla. J Am Coll Cardiol. 2004;43:1315–1324. doi:10.1016/j.jacc.2003.12.016.
51. T.Sommer, C.P.Naehle, A.Yang, et al. Strategy for safe performance of extrathoracic magnetic resonance imaging at 1.5 tesla in the presence of cardiac pacemakers in non-pacemaker-dependent patients: a prospective study with 115 examinations. Circulation. 2006;114:1285–1292. doi:10.1161/CIRCULATIONAHA.105.597013.
52. S.Nazarian, R.Hansford, A.Roguin, et al. A prospective evaluation of a protocol for magnetic resonance imaging of patients with implanted cardiac devices. An Int Med. 2011;155:415–424. doi:10.7326/0003-4819-155-7-201110040-00004.
53. J.D.Cohen, H.S.Costa, R.J.Russo. Determining the risks of magnetic resonance imaging at 1.5 tesla for patients with pacemakers and implantable cardioverter defibrillators. Am J Cardiol. 2012;110:1631–1636. doi:10.1016/j.amjcard.2012.07.033.
54. J.L.Del Ojo, F.Moya, J.Villalba, et al. Is magnetic resonance imaging safe in cardiac pacemaker recipients? Pace. 2005;28:274–278. doi:10.1111/j.1540-8159.2005.50033.x.
55. C.P.Naehle, C.Meyer, D.Thomas, et al. Safety of brain 3-t MR imaging with transmit-receive head coil in patients with cardiac pacemakers: pilot prospective study with 51 examinations. Radiology. 2008;249:991–1001. doi:10.1148/radiol.2493072195.
56. J.R.Gimbel. Magnetic resonance imaging of implantable cardiac rhythm devices at 3.0 tesla. Pace. 2008;31:795–801. doi:10.1111/j.1540-8159.2008.01117.x.
57. J.A.Coman, D.A.Sandler, J.R.Thomas. Implantable cardiac defibrillator interactions with magnetic resonance imaging at 1.5 tesla. Am Heart Assoc. 2004;43:138A.
58. C.P.Naehle, K.Strach, D.Thomas, et al. Magnetic resonance imaging at 1.5-t in patients with implantable cardioverter-defibrillators. J Am Coll Cardiol. 2009;54:549–555. doi:10.1016/j.jacc.2009.04.050.
59. A.F.Pulver, M.D.Puchalski, D.J.Bradley, et al. Safety and imaging quality of MRI in pediatric and adult congenital heart disease patients with pacemakers. Pace. 2009;32:450–456. doi:10.1111/j.1540-8159.2009.02304.x.
60. J.R.Gimbel, E.Kanal, K.M.Schwartz, et al. Outcome of magnetic resonance imaging (MRI) in selected patients with implantable cardioverter defibrillators (ICDs). Pace. 2005;28:270–273. doi:10.1111/j.1540-8159.2005.09520.x.
61. C.P.Naehle, J.Kreuz, K.Strach, et al. Safety, feasibility, and diagnostic value of cardiac magnetic resonance imaging in patients with cardiac pacemakers and implantable cardioverters/defibrillators at 1.5 t. Am Heart J. 2011;161:1096–1105. doi:10.1016/j.ahj.2011.03.007.
62. O.Mesubi, G.Ahmad, J.Jeudy, et al. Impact of ICD artifact burden on late gadolinium enhancement cardiac MR imaging in patients undergoing ventricular tachycardia ablation. Pace. 2014;37:1274–1283. doi:10.1111/pace.12405.
63. P.Nordbeck, G.Ertl, O.Ritter. Magnetic resonance imaging safety in pacemaker and implantable cardioverter defibrillator patients: how far have we come? Eur Heart J. 2015;36:1505–1511. doi:10.1093/eurheartj/ehv086.• This is a very important paper about magnetic resonance imaging safety in pacemaker and implantable cardioverter defibrillator patients.